Literature DB >> 6164990

Ribosomal RNA cleavage, nuclease activation and 2-5A(ppp(A2'p)nA) in interferon-treated cells.

D H Wreschner, T C James, R H Silverman, I M Kerr.   

Abstract

Ribosomal RNA (rRNA) in intact ribosomes is cleaved into discrete products on incubation of reticulocyte lysates or L-cell extracts with ppp(A2'p)3A. Cleavage of rRNA may, therefore, provide a useful assay for 2-5A (ppp)A2'p)nA; n = 2 to 4) or for the presence of a 2-5A-dependent nuclease. The results with reticulocyte lysates differed from those obtained in the L-cell-free system in that (a) a different RNA cleavage pattern was produced (with added L-cell ribosomes) and (b) cleavage was fully activated by the analogue ppp(A2'p)3A3'pCp. As might be expected from the relatively high levels of 2-5A present in interferon-treated, encephalomyocarditis virus (EMC)-infected L-cells, rRNA extracted from these cells was also cleaved. The cleavage pattern observed overlapped with that obtained on incubation of an L-cell-free system with 2-5A. Thus, not only is 2-5A present, but the 2-5A-dependent nuclease also appears to be active, in interferon-treated, EMC-infected L-cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6164990      PMCID: PMC326782          DOI: 10.1093/nar/9.7.1571

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  21 in total

1.  Interferon action may be mediated by activation of a nuclease by pppA2'p5'A2'p5'A.

Authors:  C Baglioni; M A Minks; P A Maroney
Journal:  Nature       Date:  1978-06-22       Impact factor: 49.962

2.  pppA2'p5'A2'p5'A: an inhibitor of protein synthesis synthesized with an enzyme fraction from interferon-treated cells.

Authors:  I M Kerr; R E Brown
Journal:  Proc Natl Acad Sci U S A       Date:  1978-01       Impact factor: 11.205

3.  Specific inactivation of ribosomes by colicin E3 in vitro and mechanism of immunity in colicinogenic cells.

Authors:  C M Bowman; J Sidikaro; M Nomura
Journal:  Nat New Biol       Date:  1971-12-01

4.  Met-tRNAfMet binding to 40S ribosomal subunits: a site for the regulation of initiation of protein synthesis by hemin.

Authors:  M J Clemens; E C Henshaw; H Rahamimoff; I M London
Journal:  Proc Natl Acad Sci U S A       Date:  1974-08       Impact factor: 11.205

5.  Effect of interferon treatment on cellular messenger RNA.

Authors:  H B Levy; F L Riley
Journal:  Proc Natl Acad Sci U S A       Date:  1973-12       Impact factor: 11.205

6.  Interferon action--sequence specificity of the ppp(A2'p)nA-dependent ribonuclease.

Authors:  D H Wreschner; J W McCauley; J J Skehel; I M Kerr
Journal:  Nature       Date:  1981-01-29       Impact factor: 49.962

7.  Interaction between membrane functions and protein synthesis in reticulocytes. Isolation of RNase M, a membrane component inhibiting protein synthesis through specific endonucleolytic activity.

Authors:  D Wreschner; D Melloul; M Herzberg
Journal:  Eur J Biochem       Date:  1978-09-01

8.  Interferon-mediated effect on ribosomal RNA metabolism.

Authors:  L E Maroun
Journal:  Biochim Biophys Acta       Date:  1978-01-26

9.  Analysis of single- and double-stranded nucleic acids on polyacrylamide and agarose gels by using glyoxal and acridine orange.

Authors:  G K McMaster; G G Carmichael
Journal:  Proc Natl Acad Sci U S A       Date:  1977-11       Impact factor: 11.205

10.  Inhibition of cell-free protein synthesis by pppA2'p5'A2'p5'A: a novel oligonucleotide synthesized by interferon-treated L cell extracts.

Authors:  M J Clemens; B R Williams
Journal:  Cell       Date:  1978-03       Impact factor: 41.582

View more
  87 in total

1.  Basis for regulated RNA cleavage by functional analysis of RNase L and Ire1p.

Authors:  B Dong; M Niwa; P Walter; R H Silverman
Journal:  RNA       Date:  2001-03       Impact factor: 4.942

2.  Inhibition of RNase L and RNA-dependent protein kinase (PKR) by sunitinib impairs antiviral innate immunity.

Authors:  Babal Kant Jha; Irina Polyakova; Patricia Kessler; Beihua Dong; Benjamin Dickerman; Ganes C Sen; Robert H Silverman
Journal:  J Biol Chem       Date:  2011-06-02       Impact factor: 5.157

3.  Similarities between Argonautes and the alpha-sarcin-like ribotoxins: Implications for microRNA action.

Authors:  Edward Pichinuk; Daniel H Wreschner
Journal:  Protein Sci       Date:  2010-06       Impact factor: 6.725

Review 4.  New insights into the role of RNase L in innate immunity.

Authors:  Arindam Chakrabarti; Babal Kant Jha; Robert H Silverman
Journal:  J Interferon Cytokine Res       Date:  2010-12-29       Impact factor: 2.607

5.  A mammalian 2-5A system functions as an antiviral pathway in transgenic plants.

Authors:  A Mitra; D W Higgins; W G Langenberg; H Nie; D N Sengupta; R H Silverman
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

Review 6.  A scientific journey through the 2-5A/RNase L system.

Authors:  Robert H Silverman
Journal:  Cytokine Growth Factor Rev       Date:  2007-07-27       Impact factor: 7.638

7.  Inhibition of polypeptide chain initiation in Daudi cells by interferons. Evidence that activity of initiation factor eIF-2 and availability of mRNA are unimpaired.

Authors:  M J Clemens; V J Tilleray
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

Review 8.  Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response.

Authors:  Robert H Silverman
Journal:  J Virol       Date:  2007-09-05       Impact factor: 5.103

9.  2-5A accumulates to high levels in interferon-treated, vaccinia virus-infected cells in the absence of any inhibition of virus replication.

Authors:  A P Rice; W K Roberts; I M Kerr
Journal:  J Virol       Date:  1984-04       Impact factor: 5.103

10.  Expression of the E3L gene of vaccinia virus in transgenic mice decreases host resistance to vaccinia virus and Leishmania major infections.

Authors:  Elena Domingo-Gil; Eva Pérez-Jiménez; Iván Ventoso; José L Nájera; Mariano Esteban
Journal:  J Virol       Date:  2007-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.